Information  X 
Enter a valid email address

Yourgene Health PLC (YGEN)


Wednesday 15 September, 2021

Yourgene Health PLC

Share option awards

RNS Number : 7857L
Yourgene Health PLC
15 September 2021

Yourgene Health plc

("Yourgene" or the "Group" or the "Company")


Share option awards


Manchester, UK - 15 September 2021:   Yourgene (AIM: YGEN), the international molecular diagnostics group, announces an award of share options.


Award of options

The Company has today issued 1,160,000 options over Ordinary Shares of 0.1p under the Company's Enterprise Management Incentive (EMI) and unapproved share option schemes to a number of individuals in the UK and international subsidiaries.

The options are exercisable in three tranches over three financial years and are subject to certain performance conditions. The options awarded are exercisable up to 14 September 2031, at a price of 15 pence per share representing an approximation of the 30 day average share price.

Following the award of these new options, and taking into account lapsed options, the Company has 59,459,172 shares under its market-based and performance-based option schemes.


This announcement contains inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.


Yourgene Health plc

Lyn Rees, Chief Executive Officer

Tel: +44 (0)161 669 8122

[email protected]

Barry Hextall, Chief Financial Officer

Joanne Cross, Director of Marketing

Cairn Financial Advisers LLP (NOMAD)

Tel: +44 (0)20 7213 0880

Liam Murray / James Caithie / Ludovico Lazzaretti



Singer Capital Markets (Joint Corporate Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / Tom Salvesen / George Tzimas

Stifel Nicolaus Europe Limited (Joint Corporate Broker)

Tel: +44 (0)20 7710 7600

Nicholas Moore / Matthew Blawat / Ben Maddison

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or  [email protected]

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / Mob: 07584 391 303 



About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genomic services and technologies. The Group works in partnership with global leaders in DNA technology to advance diagnostic science. 


Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship in vitro diagnostic products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping.


Yourgene has a range of innovative DNA sample preparation platforms, powered by Ranger® Technology, the Yourgene LightBench® and Yourgene QS250, ideal for cell-free DNA applications in NIPT and oncology including liquid biopsy.


Yourgene Genomic Services is a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.


Yourgene Health is headquartered in Manchester, UK with facilities in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". Follow us on  LinkedIn  and  Twitter .  Further information is available at


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t